Zoryve (Roflumilast) is NOT Indicated for Perioral Dermatitis
Zoryve (roflumilast cream) should not be used as a standard treatment for perioral dermatitis, as it lacks FDA approval, guideline support, or robust clinical trial evidence for this indication. While one case report suggests potential benefit, this represents insufficient evidence to recommend its use for perioral dermatitis in clinical practice.
FDA-Approved Indications
Roflumilast cream is FDA-approved for:
- 0.3% formulation: Plaque psoriasis (including intertriginous areas) in patients ≥6 years 1
- 0.15% formulation: Mild to moderate atopic dermatitis in patients ≥6 years 1
- 0.05% formulation: Mild to moderate atopic dermatitis in patients 2-5 years 1
Perioral dermatitis is not among these approved indications.
Evidence Assessment
Guideline Evidence
The 2025 American Academy of Dermatology guidelines provide strong recommendations for roflumilast cream in atopic dermatitis, based on high-quality evidence from multiple phase III trials involving 1,427 participants 2. However, these guidelines make no mention of perioral dermatitis as an indication.
Available Research for Perioral Dermatitis
The only evidence for perioral dermatitis consists of a single 2026 case report 3 describing a 30-year-old woman whose periorificial dermatitis cleared in 5 days with roflumilast 0.3% cream, with sustained remission at 11 months.
Critical limitations of this evidence:
- Single case report (lowest level of evidence)
- No controlled comparison
- No assessment of whether this represents typical response
- Insufficient to establish safety or efficacy in this population
Clinical Reasoning
While roflumilast's anti-inflammatory mechanism (PDE4 inhibition) could theoretically benefit perioral dermatitis, extrapolating from atopic dermatitis or psoriasis data is inappropriate because:
- Different pathophysiology: Perioral dermatitis has distinct triggers (often steroid-induced) and inflammatory patterns
- Lack of safety data: The specific risks in perioral dermatitis patients are unknown
- Alternative treatments exist: Established therapies include topical metronidazole, azelaic acid, oral tetracyclines, and steroid cessation
Practical Recommendation
For perioral dermatitis, use evidence-based first-line treatments:
- Discontinue topical steroids (if applicable)
- Topical metronidazole or azelaic acid
- Oral tetracyclines (doxycycline, minocycline) for moderate-severe cases
- Sulfur-based preparations
Reserve roflumilast for its approved indications where robust evidence supports its use. Off-label use based on a single case report exposes patients to unknown risks without established benefit.
Important Caveats
If considering off-label roflumilast for refractory perioral dermatitis after standard therapies fail:
- Document informed consent regarding off-label use
- Monitor closely for adverse effects (application site pain reported in 1.5% of atopic dermatitis patients 2)
- Be aware that insurance may not cover off-label use
- Consider that the 0.3% concentration used in the case report is the psoriasis formulation, not the atopic dermatitis strength